OPKO Health: Deeply Mispriced Ahead Of Major Catalysts [Seeking Alpha]
Opko Health, Inc. (OPK)
Last opko health, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investor.opko.com
Company Research
Source: Seeking Alpha
In partnership with Merck, Regeneron, and BARDA, it is developing ModeX's product candidates aimed at treating COVID-19, influenza, solid tumors, and blood cancers, as well as vaccines against EBV. Additionally, OPKO's balance sheet continues to strengthen, with total debt reaching $395.4 million at the end of Q3, down 22.8% year-over-year. Wall Street analysts project that, thanks to OPKO's revenue growth, its P/S ratio will fall to 1.43x in 2030, which, again, indicates that it is trading at a discount. As a result, I believe OPKO Health's risk/reward profile is attractive for long-term investors. AleksandarNakic/E+ via Getty Images After studying the pipeline of OPKO Health ( OPK ), I chose it as my top idea for 2026. However, Wall Street still doesn't see the potential of its tetraspecific and trispecific monoclonal antibodies , such as MDX2004, MDX2003, and This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of OPK
Show less
Read more
Impact Snapshot
Event Time:
OPK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPK alerts
High impacting Opko Health, Inc. news events
Weekly update
A roundup of the hottest topics
OPK
News
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism [Yahoo! Finance]Yahoo! Finance
- OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismGlobeNewswire
- GeneDx CEO Katherine Stueland talks shaking up rare disease diagnosis [Yahoo! Finance]Yahoo! Finance
- Miami as a gateway: Taiwan's quiet economic strategy in the Americas [Yahoo! Finance]Yahoo! Finance
- Is OPKO Health (OPK) Pricing Reflect Its DCF Upside Despite Weak Long Term Returns [Yahoo! Finance]Yahoo! Finance
OPK
Earnings
- 10/29/25 - Beat
OPK
Sec Filings
- 11/21/25 - Form 4
- 11/20/25 - Form 4
- 11/19/25 - Form 4
- OPK's page on the SEC website